Clinical and Experimental Reproductive Medicine

  • 제42권2호
  • /
  • Pages.62-66
  • /
  • 2015
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of corifollitropin alfa followed by recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist protocol for Korean women undergoing assisted reproduction

  • Park, Hyo Young (Laboratory of Reproductive Medicine, Creation and Love Women's Hospital) ;
  • Lee, Min Young (Department of Obstetrics and Gynecology, Center for Infertility and Recurrent Miscarriage, Creation and Love Women's Hospital) ;
  • Jeong, Hyo Young (Department of Obstetrics and Gynecology, Center for Infertility and Recurrent Miscarriage, Creation and Love Women's Hospital) ;
  • Rho, Yong Sook (Department of Obstetrics and Gynecology, Center for Infertility and Recurrent Miscarriage, Creation and Love Women's Hospital) ;
  • Song, Sang Jin (Laboratory of Reproductive Medicine, Creation and Love Women's Hospital) ;
  • Choi, Bum-Chae (Department of Obstetrics and Gynecology, Center for Infertility and Recurrent Miscarriage, Creation and Love Women's Hospital)
  • 투고 : 2015.01.13
  • 심사 : 2015.04.22
  • 발행 : 2015.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To evaluate the effect of a gonadotropin-releasing hormone (GnRH) antagonist protocol using corifollitropin alfa in women undergoing assisted reproduction. Methods: Six hundred and eighty-six in vitro fertilization-embryo transfer (IVF)/ intracytoplasmic sperm injection (ICSI) cycles were analyzed. In 113 cycles, folliculogenesis was induced with corifollitropin alfa and recombinant follicle stimulating hormone (rFSH), and premature luteinizing hormone (LH) surges were prevented with a GnRH antagonist. In the control group (573 cycles), premature LH surges were prevented with GnRH agonist injection from the midluteal phase of the preceding cycle, and ovarian stimulation was started with rFSH. The treatment duration, quality of oocytes and embryos, number of embryo transfer (ET) cancelled cycles, risk of ovarian hyperstimulation syndrome (OHSS), and the chemical pregnancy rate were evaluated in the two ovarian stimulation protocols. Results: There were no significant differences in age and infertility factors between treatment groups. The treatment duration was shorter in the corifollitropin alfa group than in the control group. Although not statistically significant, the mean numbers of matured (86.8% vs. 85.1%) and fertilized oocytes (84.2% vs. 83.1%), good embryos (62.4% vs. 60.3%), and chemical pregnancy rates (47.2% vs. 46.8%) were slightly higher in the corifollitropin alfa group than in the control group. In contrast, rates of ET cancelled cycles and the OHSS risk were slightly lower in the corifollitropin alfa group (6.2% and 2.7%) than in the control group (8.2% and 3.5%), although these differences were also not statistically significant. Conclusion: Although no significant differences were observed, the use of corifollitropin alfa seems to offer some advantages to patients because of its short treatment duration, safety, lower ET cancellation rate and reduced risk of OHSS.

키워드

참고문헌

  1. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997;18:71-106.
  2. Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 2009;15:309-21. https://doi.org/10.1093/humupd/dmn065
  3. Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2004;89:2062-70. https://doi.org/10.1210/jc.2003-031766
  4. Corifollitropin Alfa Dose-finding Study Group. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Hum Reprod 2008;23:2484-92. https://doi.org/10.1093/humrep/den288
  5. Loutradis D, Vlismas A, Drakakis P. Corifollitropin alfa: a novel long-acting recombinant follicle-stimulating hormone agonist for controlled ovarian stimulation. Womens Health (Lond Engl) 2010;6:655-64. https://doi.org/10.2217/whe.10.56
  6. Balen AH, Mulders AG, Fauser BC, Schoot BC, Renier MA, Devroey P, et al. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. J Clin Endocrinol Metab 2004;89:6297-304. https://doi.org/10.1210/jc.2004-0668
  7. Bouloux PM, Handelsman DJ, Jockenhovel F, Nieschlag E, Rabinovici J, Frasa WL, et al. First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Hum Reprod 2001;16: 1592-7. https://doi.org/10.1093/humrep/16.8.1592
  8. Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, De Bie JJ, Voortman G. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Hum Reprod 2002;17:1987-93. https://doi.org/10.1093/humrep/17.8.1987
  9. Tarlatzis BC, Griesinger G, Leader A, Rombauts L, Ijzerman-Boon PC, Mannaerts BM. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. Reprod Biomed Online 2012;24: 410-9. https://doi.org/10.1016/j.rbmo.2012.01.005
  10. Mahmoud Youssef MA, van Wely M, Aboulfoutouh I, El-Khyat W, van der Veen F, Al-Inany H. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. Fertil Steril 2012;97:876-85. https://doi.org/10.1016/j.fertnstert.2012.01.092
  11. Veeck LL. Fertilization and early embryonic development. Curr Opin Obstet Gynecol 1992;4:702-11.
  12. Olivius C, Friden B, Borg G, Bergh C. Why do couples discontinue in vitro fertilization treatment? A cohort study. Fertil Steril 2004;81:258-61. https://doi.org/10.1016/j.fertnstert.2003.06.029
  13. Verberg MF, Eijkemans MJ, Heijnen EM, Broekmans FJ, de Klerk C, Fauser BC, et al. Why do couples drop-out from IVF treatment? A prospective cohort study. Hum Reprod 2008;23:2050-5. https://doi.org/10.1093/humrep/den219
  14. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC, et al. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009;24:3063-72. https://doi.org/10.1093/humrep/dep291
  15. Corifollitropin alfa Ensure Study Group. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-bodyweight women. Reprod Biomed Online 2010;21:66-76. https://doi.org/10.1016/j.rbmo.2010.03.019
  16. Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992;58:888-96. https://doi.org/10.1016/S0015-0282(16)55430-2
  17. Polyzos NP, Devos M, Humaidan P, Stoop D, Ortega-Hrepich C, Devroey P, et al. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study. Fertil Steril 2013;99:422-6. https://doi.org/10.1016/j.fertnstert.2012.09.043

피인용 문헌

  1. Corifollitropin alfa in different variants of ovarian response in assisted reproductive technology programmes: literature review vol.2021, pp.3, 2015, https://doi.org/10.21518/2079-701x-2021-3-33-38